OAB Treatment Market 2020 Productivity Data Analysis by Key Company's (Astellas Pharma, Allergan, Pfizer, Teva (Astellas Pharma, Allergan, Pfizer, Teva) | Global Forecast to 2025

Global OAB Treatment Market: Overview

The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence

Get Access to Report Sample @ https://www.businessindustryreports.com/sample-request/240473

Global OAB Treatment Market: Growth Factors

The growth of market is majorly driven by the increasing geriatric population and consequently rising prevalence of bladder overactivity, aggressive marketing strategies by pharma companies, and the development of new therapies to treat bladder overactivity. However, the undesired systemic effects caused by anticholinergics may hinder the growth of the market to a certain extent

Global OAB Treatment Market: Segmentation

On the basis of Product Type, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Anticholinergics, Mirabegron, Botox. Based on End Users/Applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Idiopathic Overactive Bladder, Neurogenic Overactive Bladder.

Global OAB Treatment Market: Regional Analysis

Asia Pacific was a prominent market for OAB Treatments in 2016. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income. Increased spending on home interiors is fuelling the OAB Treatment market in Asia Pacific.

There are several manufacturers of OAB Treatments in Europe and North America. In North America, the demand for OAB Treatments is primarily driven by the residential sector. Improved standards of living and rising usage of OAB Treatments for flooring purpose are anticipated to drive the market in North America.

Global OAB Treatment Market: Competitive Players

Some of the major players that operate in the Global OAB Treatment Market are Astellas Pharma, Allergan, Pfizer, Teva (Activas), Johnson & Johnson.

Buy OAB Treatment Market analysis & forecast 2020-2024 Report along with complete TOC@ https://www.businessindustryreports.com/buy-now/240473/single

Global OAB Treatment Market: Regional Segment Analysis

North America (U.S. and Canada)

Latin America (Mexico, Brazil, Peru, Chile, and others)

Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)

Eastern Europe (Poland and Russia)

Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)

Middle East and Africa (GCC, Southern Africa, and North Africa)

What Report Provides

Full in-depth analysis of the parent market

Important changes in market dynamics

Segmentation details of the market

Former, on-going, and projected market analysis in terms of volume and value

Assessment of niche industry developments

Market share analysis

Key strategies of major players

Emerging segments and regional markets

Testimonials to companies in order to fortify their foothold in the market.

Get Best Discount On This Report @ https://www.businessindustryreports.com/check-discount/240473�

Latest Industry Updates:

Pfizer Inc. (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz� (fesoterodine fumarate) 8 mg once daily in patients with overactive bladder (OAB) compared to Toviaz 4 mg once daily or placebo met its primary endpoint. The primary endpoint was change in mean number of urge urinary incontinence episodes per 24 hours from baseline to week 12. Toviaz 8 mg reduced urge urinary incontinence in patients with OAB statistically significantly more than Toviaz 4 mg. The efficacy of both doses was statistically significant versus placebo. The recommended starting dose of Toviaz is 4 mg once daily.

The safety and tolerability profile of both Toviaz doses in this study were consistent with previous studies. Adverse events occurred more frequently among subjects receiving the 8 mg dose of Toviaz than the 4 mg dose, and both doses of Toviaz had adverse event rates greater than placebo. The most common treatment-emergent adverse events were dry mouth, constipation and urinary tract infection.

"We are aware of no other approved overactive bladder medication that has demonstrated statistically superior efficacy of its higher dose versus lower dose in reducing urge urinary incontinence in a randomized controlled prospective study," said Steven J. Romano, M.D., senior vice president and medicines development group head, Primary Care Business Unit, Pfizer Inc. "This study further confirmed the efficacy of Toviaz 4 mg and the results show that Toviaz 8 mg can further reduce symptoms in patients who require additional efficacy beyond the 4 mg dose.

Table of Contents:

Global OAB Treatment Market Report 2020

1 OAB Treatment Definition

2 Global OAB Treatment Market Major Player Share and Market Overview

3 Major Player OAB Treatment Business Introduction

4 Global OAB Treatment Market Segmentation (Region Level)

5 Global OAB Treatment Market Segmentation (Product Type Level)

6 Global OAB Treatment Market Segmentation (Industry Level)

7 Global OAB Treatment Market Segmentation (Channel Level)

8 OAB Treatment Market Forecast 2020-2024

................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.